6 Undervalued Biotechnology Stocks for Wednesday, November 20
Discover the top 6 undervalued Biotechnology stocks for Wednesday, November 20 based on AAII’s Stock Grades.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Commentary & Analysis
6 Undervalued Pharmaceuticals Stocks for Wednesday, January 24
Discover the top 6 undervalued Pharmaceuticals stocks for Wednesday, January 24 based on AAII’s Stock Grades.Jenna Brashear
5 Undervalued Pharmaceuticals Stocks for Friday, November 10
Discover the top 5 undervalued Pharmaceuticals stocks for Friday, November 10 based on AAII’s Stock Grades.Eunice Kim
6 Undervalued Pharmaceuticals Stocks for Tuesday, March 21
Discover the top 6 undervalued Pharmaceuticals stocks for Tuesday, March 21 based on AAII’s Stock Grades.Jack Gilleland
3 Undervalued Pharmaceuticals Stocks for Friday, January 20
Discover the top 3 undervalued Pharmaceuticals stocks for Friday, January 20 based on AAII’s Stock Grades.Jack Gilleland
Financial Summary
| Share Statistics | MBRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.1 | $252.6 | 1% |
|
| Shares Out (Mil) | 4.1 | 52.3 | 12% |
|
| Institutional Ownership | 83.1% | 92.1% | 51% |
|
| Float (Mil) | 5.3 | 40.2 | 13% |
|
| Beta | 1.74 | 0.95 | 88% |
|
| Avg Daily Volume (000s) | 2,284 | 455 | 84% |
|
| Price Change (52-week) |
(97.8%) | 52.9% | 2% |
|
| Growth | MBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (14.1%) | (9.9%) | 26% |
|
| EPS (5yr) | 46.7% | 16.0% | 91 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (53.0%) | (15.6%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | MBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($41) | ($43) | 18% |
|
| EPS (TTM) | ($19.965) | ($1.600) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($24) | ($31) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 12% |
|
| Enterprise Value (Q1) (Mil) | $4 | $180 | 5% |
|
| Valuation | MBRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.14 | 2.56 | 2% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | MBRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (182.5%) | (49.8%) | 2% |
|
| ROE | (532.0%) | (55.5%) | 1% |
|
| Liabilities to Assets | 35.0% | 30.3% | 26% |
|
| F-Score | 3 | 3 | 19% |
|
Moleculin Biotech, Inc. did not pass any screens on 7/31/2026.
